PHARMACOTHERAPY: Colchicine for recurrent pericarditis —what's new in CORP-2?

    loading  Checking for direct PDF access through Ovid

Abstract

In the CORP-2 trial, patients with multiple recurrences of idiopathic or autoimmune pericarditis were randomly assigned to receive colchicine or placebo, in addition to standard anti-inflammatory therapy. After 6 months, colchicine significantly reduced recurrent pericarditis rates. Are we moving closer to a reliable treatment for this common disease?

Related Topics

    loading  Loading Related Articles